| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
EVA TSALAKIAN
,
VICTOR SCHNEIDER
and
JOHN E. GERICH
* The Departments of Medicine (Endocrinology), University of California at San Diego San Franciscot The Veterans Administration Hospital La Jolla, California
The Metabolic Research Unit San Franciscot
University of California San Francisco
Reprint requests to Dr. Deftos.
The effect of somatostatin on plasma parathyroid hormone (PTH) was studied in 6 subjects with normal parathyroid function and one patient with a parathyroid adenoma. In 5 subjects, including the one with the parathyroid adenoma, plasma PTH was measured by radioimmunoassay during a 4-hour infusion of somatostatin (500 µg/h). In 2 subjects, PTH responses to EDTA were compared with those observed during a simultaneous infusion of somatostatin and EDTA. In no instance was there a discernible effect of the somatostatin infusion on plasma PTH. These results demonstrate that somatostatin does not suppress plasma PTH.
Supported by Grants from the National Institutes of Health (AM 15888, AM07048, AM 12763, and HD08340), the American Cancer Society (PDT-25A), and the Veterans Administration.
Dr. Deftos is a Clinical Investigator of the Veterans Administration.
Received January 2, 1976.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |